UNSPSC 51401514: Prazepam

This classification denotes a benzodiazepine with the molecular formula C19H17ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q30VCC064M, chemically known as 7-chloro-1-cyclopropylmethyl-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one but generally known as prazepam, which bears US NIH Compound Identifier 4890. European Medicines Agency schedules Prazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10006MIG. The term PRAZEPAM is an International Non-Proprietary Name.

UNSPSC 51401514 Prazepam is a Commodity code that in recent state and local procurement appears broadly misapplied—the code nominally addresses a specific benzodiazepine pharmaceutical, yet the recent opportunities tagged under it span naloxone procurement, therapeutic pharmacy initiative planning, and generic multi-source pharmaceutical supply agreements that have no direct connection to prazepam specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Work solicited ranges from direct purchase of naloxone and drug deactivation systems through county health procurement, to state-level market research on direct-to-manufacturer pharmacy programs, to wholesale pharmaceutical supply contracting across multiple state and local jurisdictions. The scope mismatch suggests either coding error in the source or a broader use of the prazepam code to capture pharmaceutical procurement activity that falls outside its stated commodity definition.

Recent activity concentrates in the Midwest and Southeast. The Minnesota Multistate Cooperative Purchasing Alliance RFP issued in January 2026 (due March 26, 2026) seeks generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract awards effective July 1, 2026 and a two-year initial term. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023—note the date appears inconsistent with the posting date. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026 to gather vendor information on direct-to-manufacturer prescription programs, designed to inform future formal solicitation strategy rather than award a contract immediately. No clear activity pattern supports sustained procurement under this code's nominal scope.